Bone Biologics Corp

For the period ended Mar 31, 2024. Filed May 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 14, 2024

BBLG$0.34+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Statements of Stockholders’ Equity

Consolidated Statement of Stockholders’ Equity

For the Three Months ended March 31, 2024

(unaudited)

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
	Shares	Amount	Capital	Equity	Equity
Balance at December 31, 2023	534,238	$534	$83,814,785	$(80,908,958)	$2,906,361
Fair value of vested stock options	-	-	52,681	-	52,681
Options issued to settle accrued bonus	-	-	77,400	-	77,400
Proceeds from sale of common stock in public offering, net of offering costs of $490,227	344,938	345	1,503,994	-	1,504,339
Exercise of pre-funded warrants	137,313	137	-	-	137
Net Loss	-	-	-	(865,970)	(865,970)
Balance at March 31, 2024	1,016,489	$1,016	$85,448,860	$(81,774,928)	$3,674,948

Consolidated Statement of Stockholders’ Equity

For the Three Months ended March 31, 2023

(unaudited)

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
	Shares	Amount	Capital	Equity	Equity
Balance at December 31, 2022	63,820	$64	$77,907,471	$(71,960,227)	$5,947,308
Fair value of vested stock options issued to employees and directors	-	-	44,764	-	44,764
Exercise of warrants	5,837	6	(6)	-	-
Extinguishment of warrant liability upon exercise of warrants	-	-	490,226	-	490,226
Net Loss	-	-	-	(3,709,899)	(3,709,899)
Balance at March 31, 2023	69,657	$70	$78,442,455	$(75,670,126)	$2,772,399

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.